Disability-adjusted-life-years losses in postmenopausal women with osteoporosis: a burden of illness study

Josep Darbà, Lisette Kaskens, Nuria Pérez-Álvarez, Santiago Palacios, José Luis Neyro, Javier Rejas, Josep Darbà, Lisette Kaskens, Nuria Pérez-Álvarez, Santiago Palacios, José Luis Neyro, Javier Rejas

Abstract

Background: To estimate the disability-adjusted life years (DALY) in a nationwide representative sample of postmenopausal women with osteoporosis. The effects of drug-based therapy and risk factors for osteoporotic bone fractures on DALY losses were also explored.

Methods: DALY were estimated based on participant's clinical characteristics and Health-Related Quality-of-Life (HRQoL) data obtained from a cross-sectional, epidemiological one-visit study (the GINERISK study). The study enrolled postmenopausal women (at least 12-months after their last menstrual period) with osteoporosis, above 18-years old, who attended Spanish outpatient Gynaecology clinics. HRQoL was assessed using the generic SF-12v2 questionnaire, which was used to derive disutility values. Mortality rates were extracted from the Spanish national statistics database. Factors explored to be associated with DALY losses were examined using ANOVA, ANCOVA and MANCOVA models.

Results: DALY could be computed in 2,782 (67%) out of 4,157 postmenopausal women, with a mean (95% CI) age of 61.0 (60.7-61.2) years. Overall individual undiscounted DALY per woman were 6.1 (5.9-6.2), resulting to be significantly higher in women with severe osteoporosis with prior bone fracture; 7.8 (7.2-8.4) compared to osteoporotic women [5.8 (5.6-6.0)] or postmenopausal women with a BMD > -2.5 T-score that received a drug-based therapy [6.2 (5.8-6.5)]; F = 27.0 (P < 0.01). Models explaining the variation in the levels of health based on the use of a selective estrogen receptor modulator (SERM) or possession of risk factors for osteoporotic BF were found (P < 0.05).

Conclusions: DALY losses were considerable amongst postmenopausal women with osteoporosis. Not having a prior bone fracture, being older, using a SERM and having less osteoporotic risk factors were all linked to less DALY losses.

References

    1. National Osteoporosis Foundation . Clinician’s Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2010. pp. 1–3.
    1. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict ocurrence of osteoporotic fractures. BMJ. 1996;312:1254–1259. doi: 10.1136/bmj.312.7041.1254.
    1. Azagra R, Roca G, Encabo G, Prieto D, Aguyé A, Zwart M, et al. Prediction of absolute risk of fragility fracture at 10 years in a Spanish population: validation of the WHO FRAX ™ tool in Spain. BMC Musculoskelet Disord. 1996;12:30. doi: 10.1186/1471-2474-12-30.
    1. Palacios S, Borrego RS, Forteza A. The importance of preventive health care in post-menopausal women. Maturitas. 2005;52(Suppl 1):S53–60. doi: 10.1016/j.maturitas.2005.06.013.
    1. Ferrer J, Neyro JL, Estevez A. Identification of risk factors for prevention and early diagnosis of a-symptomatic post-menopausal women. Maturitas. 2005;52(Suppl 1):S7–22. doi: 10.1016/j.maturitas.2005.06.017.
    1. WHO Scientific Group . WHO Technical Report Series; 921. Geneva, Switzerland: World Health Organization; 2003. Prevention and Management of Osteoporosis; pp. 2–5.
    1. Kanis JA, Black D, Cooper C, Dargent P, Dawson-Hughes B, De Laet C. A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int. 2002;13:527–536. doi: 10.1007/s001980200069.
    1. Kanis JA, Melton LJ, 3rd, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. Bone Miner Res. 1994;9:1137–1141. doi: 10.1002/jbmr.5650090802.
    1. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. WHO Technical Report Series; 843. Geneva, Switzerland: World Health Organization. 1994:5.
    1. Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B, et al. Assessment of fracture risk. Osteoporos Int. 2005;16:581–589. doi: 10.1007/s00198-004-1780-5.
    1. Viswanathan HN, Curtis JR, Yu J, White J, Merinar C, Stolshek BS, et al. Direct healthcare costs of osteoporosis-related fractures in managed care patients receiving pharmacological osteoporosis therapy. Appl Health Econ Health Policy. 2012;10:163–173. doi: 10.2165/11598590-000000000-00000.
    1. Cooper C, Campion G, Melton LJ., III Hip fractures in the elderly: a world-wide projection. Osteoporos Int. 1992;2:285–289. doi: 10.1007/BF01623184.
    1. Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos Int. 1997;7:407–413. doi: 10.1007/PL00004148.
    1. Johnell O, Kanis JA. An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos Int. 2004;15:897–902. doi: 10.1007/s00198-004-1627-0.
    1. Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA. 1995;273(1):59–65. doi: 10.1001/jama.1995.03520250075037.
    1. Gènova-Maleras R, Catalá-López F, de Larrea-Baz NF, Álvarez-Martín E, Morant-Ginestar C. The burden of premature mortality in Spain using standard expected years of life lost: a population-based study. BMC Public Health. 2011;11:787. doi: 10.1186/1471-2458-11-787.
    1. Gardner JW, Sanborn JS. Years of potential life lost (YPLL)–what does it measure? Epidemiology. 1990;1:322–329. doi: 10.1097/00001648-199007000-00012.
    1. Palacios S, Neyro JL, Puertas JC, Fernandez de Cabo S. Clinical profile of Spanish postmenopausal women with a diagnosis of osteoporosis and risk factors for endometrial pathology, breast cancer, and cardiovascular disease. Menopause. 2013;20(8):852–859. doi: 10.1097/GME.0b013e318280a2f6.
    1. Fox-Rushby JA, Hanson K. Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis. Health Policy Plan. 2001;16:326–31. doi: 10.1093/heapol/16.3.326.
    1. Murray CJL, Acharya AK. Understanding DALYs. J Health Economics. 1997;16:703–730. doi: 10.1016/S0167-6296(97)00004-0.
    1. Mathers CD, Vos T, Lopez AD, Salomon J, Ezzati M. Global Program on Evidence for Health Policy. 20. Geneva: World Health Organization; 2001. National Burden of Disease Studies: A Practical Guide.
    1. Instituto Nacional de Estadistíca (INE) Tablas de mortalidad de la población de España por año, sexo, edad y funciones. Esperanza de vida. [] (Accessed 15 of March 2015).
    1. Franks P, Lubetkin EI, Gold MR, Tancredi DJ, Jia H. Mapping the SF-12 to the EuroQol EQ-5D index in a national US sample. Med Decis Making. 2004;24:247–54. doi: 10.1177/0272989X04265477.
    1. Sassi F. Calculating QALYs, comparing QALY and DALY calculations. Health Policy Plan. 2006;21(5):402–408. doi: 10.1093/heapol/czl018.
    1. Sanfélix-Genovés J, Hurtado I, Sanfélix-Gimeno G, Reig-Molla B, Peiró S. Impact of osteoporosis and vertebral fractures on quality-of-life. A population-based study in Valencia, Spain (The FRAVO Study) HQLO. 2011;9:20.
    1. Cortet B, Blotman F, Debiais F, Huas D, Mercier F, Rousseaux C, et al. Management of osteoporosis and associated quality of life in post-menopausal women. BMC Musculoskelet Disord. 2011;12:7. doi: 10.1186/1471-2474-12-7.
    1. Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnel I, Petterson C, et al. Mortality after Osteoporotic Fractures. Osteoporosis Int. 2004;15:38–42. doi: 10.1007/s00198-003-1490-4.
    1. World Health Organization . The world health report: changing history. Geneva: World Health Organization; 2004.
    1. Murray CJL, Lopez AP. Global and regional descriptive epidemiology of disability. Incidence, prevalence, health expectancies and years lived with disability. In: Murray CJL, Lopez AD, editors. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge: Cambridge University Press; 1996. pp. 201–246.
    1. Murray CJL, Lopez AD, Jamison DT. The global burden of disease in 1990: summary results, sensitivity analysis and future directions. Bull World Health Organ. 1994;72(3):495–509.
    1. Anand S, Hanson K. Disability-Adjusted Life Years: A Critical Review. J Health Econ. 1997;16(6):685–702. doi: 10.1016/S0167-6296(97)00005-2.
    1. Bobadilla JL. “Priority Setting and Cost Effectiveness”. In: Janovsky K, editor. Health Policy and Systems Development: An Agenda for Research. Geneva: World Health Organization; 1996. pp. 43–60.
    1. Sambrook PN, Silverman SL, Cauley JA, Recknor C, Olson M, Su G, et al. Health-related quality of life and treatment of postmenopausal osteoporosis: results from the HORIZON-PFT. Bone. 2011;48:1298–1304. doi: 10.1016/j.bone.2011.03.719.
    1. Mortimer D, Segal L. Comparing the incomparable? A systematic review of competing techniques for converting descriptive measures of health status into QALY-weights. Med Decis Making. 2008;28:66–89. doi: 10.1177/0272989X07309642.
    1. Del Pino Montes J. Epidemiología de las fracturas osteoporóticas: las fracturas vertebrales y no vertebrales. Rev Osteoporos Metab Miner. 2010;2:S8–S12.
    1. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17:1726–1733. doi: 10.1007/s00198-006-0172-4.
    1. International Osteoporosis Foundation (IOF). Osteoporosis is an ancient disease. [] (Accessed 15 of March 2015).

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅